Literature DB >> 3367187

Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment.

C G Willett1, R M Linggood, J C Leong, L M Miketic, M A Stracher, S J Skates, D C Kushner.   

Abstract

From 1979 to 1986, the response to treatment of 53 patients with stage IA to IIB mediastinal Hodgkin's disease was evaluated by three-dimensional volumetric analysis using thoracic computed tomographic (CT) scans. The mean initial volume of mediastinal disease in 34 patients treated with mantle and para-aortic irradiation was 166 mL, whereas for 19 patients treated with two to six cycles of multiagent chemotherapy and mantle and para-aortic irradiation the mean initial volume was 446 mL. Preliminary data suggested that patients with mediastinal volumes of less than 200 mL had a lower mediastinal relapse rate (13%) than patients with volumes greater than 200 mL (32%). For 12 patients receiving six cycles of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), those with a greater than 85% reduction in volume 1 to 2 months after chemotherapy had a lower incidence of mediastinal relapse (zero of six, 0%) compared with patients having 85% or less reduction in volume (four of six, 67%). The primary value of this technique is that it provides a sensitive assessment of response to treatment and may aid in monitoring the effectiveness of a given treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367187     DOI: 10.1200/JCO.1988.6.5.819

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  1 in total

1.  Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Authors:  Salim Kanoun; Cédric Rossi; Alina Berriolo-Riedinger; Inna Dygai-Cochet; Alexandre Cochet; Olivier Humbert; Michel Toubeau; Emmanuelle Ferrant; François Brunotte; René-Olivier Casasnovas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-09       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.